Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma

Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patients and to investigate the exposure–response relatio...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancers (Basel)
Главные авторы: Balakirouchenane, David, Guégan, Sarah, Csajka, Chantal, Jouinot, Anne, Heidelberger, Valentine, Puszkiel, Alicja, Zehou, Ouidad, Khoudour, Nihel, Courlet, Perrine, Kramkimel, Nora, Lheure, Coralie, Franck, Nathalie, Huillard, Olivier, Arrondeau, Jennifer, Vidal, Michel, Goldwasser, Francois, Maubec, Eve, Dupin, Nicolas, Aractingi, Selim, Guidi, Monia, Blanchet, Benoit
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226106/
https://ncbi.nlm.nih.gov/pubmed/32283865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040931
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы